Results 271 to 280 of about 13,067,159 (317)

Basroparib inhibits YAP‐driven cancers by stabilizing angiomotin

open access: yesMolecular Oncology, EarlyView.
Basroparib, a selective tankyrase inhibitor, suppresses Wnt signaling and attenuates YAP‐driven oncogenic programs by stabilizing angiomotin. It promotes AMOT–YAP complex formation, enforces cytoplasmic YAP sequestration, inhibits YAP/TEAD transcription, and sensitizes YAP‐active cancers, including KRAS‐mutant colorectal cancer, to MEK inhibition.
Young‐Ju Kwon   +4 more
wiley   +1 more source

Impact of TyG index on coronary plaques in patients with coronary artery disease under aggressive lipid-lowering therapy. [PDF]

open access: yesFront Endocrinol (Lausanne)
Fukase T   +9 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy